Somerville, MA, United States of America

Hakan Gunaydin

This inventor holds 17 USPTO granted patents and 8 published patent applications and 10 EPO patents, primarily in Pharmaceutical Inhibitors. Top assignees: Merck Sharp + Dohme Corp., Amgen Inc., Relay Therapeutics, Inc.. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hakan Gunaydin. Retrieved from https://idiyas.com/inventor/hakan-gunaydin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17 (Patent Applications = 8)

% Patents Active = 100.0

EPO Patents = 10 (Patent Applications = 18)

Average Co-Inventor Count = 9.3

ph-index = 2

Forward Citations = 41(Granted Patents)

Location History:

Boston, MA (US) (2016 - 2019)
Somerville, MA (US) (2016 - 2024)

Company Filing History:

10 out of 2,405

Merck Sharp + Dohme Corp.

Relay Therapeutics, Inc.

patents

4. 2 out of 31

D.e. Shaw Research, LLC

patents

5. 1 out of 73

Merck Sharp & Dohme LLC

patents

where one patent can have more than one assignee

Years Active: 2016-2026

Loading Chart...

Areas of Expertise:

LRRK2 Inhibitors

PI3K-α Inhibitors

RORgammaT Inhibitors

SHP2 Phosphatase

Arginase Inhibitors

Indazole Derivatives

Pyrazole Compounds

Biaryl Acyl-Sulfonamide

KDM5 Inhibitors

Quinazolinone Compounds

Oxazolidinone Compounds

Pharmaceutical Compositions

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12760026 - Heteroaroyl amides as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2026-10-13),

2. 12581252 - Substituted pyrrolo[3,4-b]pyridines as PI3K-α inhibitors (2026-03-17),

3. 12331056 - SHP2 phosphatase inhibitors and methods of use thereof (2025-06-17),

4. 12215116 - Arginase inhibitors and methods of use (2025-02-04),

5. 12084447 - SHP2 phosphatase inhibitors and methods of use thereof (2024-09-10),

6. 12030872 - N-heteroaryl indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2024-07-09),

7. 11174248 - Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2021-11-16),

8. 11161854 - Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2021-11-02),

9. 10975084 - KDM5 inhibitors (2021-04-13),

10. 10689369 - Substituted indazole compounds as RORgammaT inhibitors and uses thereof (2020-06-23),

11. 10584121 - Heteroaryl substituted benzoic acids as RORgammaT inhibitors and uses thereof (2020-03-10),

12. 10344000 - Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof (2019-07-09),

13. 10287272 - Substituted indazole compounds as RORgammaT inhibitors and uses thereof (2019-05-14),

14. 10221142 - Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof (2019-03-05),

15. 9663508 - Biaryl acyl-sulfonamide compounds as sodium channel inhibitors (2017-05-30),

Sure, let's create an article about inventor Hakan Gunaydin:

Title: Innovator Spotlight: Hakan Gunaydin - Pioneering Pharmaceutical Breakthroughs

Introduction:

Hakan Gunaydin is a prolific inventor based in Somerville, MA, USA, known for his groundbreaking work in the pharmaceutical industry. With a total of 11 patents to his name, Gunaydin has been at the forefront of developing innovative solutions for treating complex diseases.

Latest Patents:

Gunaydin's latest patents showcase his expertise in developing cutting-edge pharmaceutical compounds. His patents include "Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof" and "Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof." These inventions aim to inhibit the LRRK2 kinase and have the potential to revolutionize the treatment of diseases like Parkinson's Disease.

Career Highlights:

Currently employed at Merck Sharp & Dohme Corporation, Gunaydin has been instrumental in driving innovation within the company. His work has not only led to the development of novel compounds but has also paved the way for future advancements in the pharmaceutical field.

Collaborations:

Gunaydin has collaborated with esteemed professionals in his field, including Blair T Lapointe and Peter H Fuller. Together, they have worked on various projects aimed at addressing unmet medical needs and improving patient outcomes.

Conclusion:

In conclusion, Hakan Gunaydin stands as a shining example of innovation in the pharmaceutical industry. His dedication to developing novel solutions for challenging diseases like Parkinson's Disease has earned him recognition as a leading figure in the field. Gunaydin's contributions continue to have a lasting impact on the healthcare landscape, offering hope for a better future.

Profile summary based on public USPTO records.